Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Monensin sodium salt (HB4882)
Description:Protein transport inhibitor. Commonly used in cytokine staining.
Purity:>98%
Mycophenolic acid (HB3987)
Description:Inosine monophosphatase dehydrogenase inhibitor
Purity:>98%
Naphthomycin B (HB3988)
Description:Ansamycin antibiotic with antibacterial and antifungal activity
Purity:>98%
Nargenicin A1 (HB3989)
Description:Antibiotic effective against gram-positive bacteria
Purity:>98%
Niclosamide (HB1435)
Description:STAT3 signaling pathway inhibitor. Antineoplastic against AML stem cells.
Purity:>98%